Ocugen Inc. (OCGN) is scheduled to report second-quarter 2021 earnings on August 6, before the market open. Ocugen is a biopharmaceutical business specializing in the development of gene treatments for blindness. In February, the company partnered with Bharat Biotech and shifted its efforts to develop COVAXIN, an advanced-stage whole-virion inactivated COVID-19 vaccine candidate, for the U.S. market. In the wake of that move, shares have gained 271% year-to-date and 1,376% over the past year. A strong set of numbers should give the stock further drive upward, so let’s take a closer look at what analysts on the Street are expecting.
https://www.tipranks.com/news/article/ocugen-q2-earnings-preview-whats-in-store?utm_source=advfn.com&utm_medium=referral
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Ocugen Charts.
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Ocugen Charts.